Table 2:
Treatment of patients classified by histologic grade, rCBV, and ADC values
| Histologic Grade | No Adjuvant Therapy | Radiotherapy | Chemotherapy (TMZ) | Chemoradiotherapy | Total |
|---|---|---|---|---|---|
| Grade II | 7 (5.6%) | 2 (1.6%) | 14 (11.2%) | 7 (5.6%) | 24% |
| Grade III | 1 (0.8%) | 0 (0%) | 6 (4.8%) | 11 (8.8%) | 14.4% |
| Grade IV | 13 (10.4%) | 0 (0%) | 2 (1.6%) | 63 (49.6%) | 61.6% |
| Total | 16.8% | 1.6% | 17.6% | 64% | 100% |
| rCBV values | |||||
| rCBV ≥ 5.195 | 11 (8.7%) | 0 (0.0%) | 4 (3.2%) | 48 (38.1%) | 50% |
| rCBV < 5.195 | 11 (8.7%) | 2 (1.6%) | 18 (14.3%) | 32 (25.4%) | 50% |
| Total | 17.5% | 1.6% | 17.5% | 63.5% | 100% |
| ADC values | |||||
| ADC < 0.799 × 10−3 mm2/s | 13 (10.3%) | 0 (0.0%) | 3 (2.3%) | 47 (37.4%) | 50% |
| ADC ≥ 0.799 × 10−3 mm2/s | 8 (6.4%) | 2 (1.6%) | 19 (15%) | 34 (27%) | 50% |
| Total | 16.7% | 1.6% | 17.3% | 64.4% | 100% |
Note:—TMZ indicates temozolomide.